



9 August 2021

SOMNOMED 2021 FULL YEAR FINANCIAL RESULTS INVESTOR CONFERENCE CALL

SomnoMed Limited (ASX SOM, or the Company) advises its 2021 Full Year Financial Results and Investor Presentation will be released to the ASX on 24th August 2021.

Following the release, management will host an investor conference call and webcast including a Q&A session. Participants are encouraged to register before the start of the call using the details below.

Date: Tuesday, 24 August 2021

Time: 11:00am (Australian Eastern Standard Time)

Webcast Link:

The audio webcast and slide presentation registration will be accessible via the following link:

<https://webcast.boardroom.media/somnomed-limited/20210824/NaN60f5013dd194c5001ac4e09b>

Dial In Details:

Investors wishing to ask questions will be required to register and dial-in via the below conference dial in details.

Audio access dial-in numbers:

Conference ID:	10015341
Australia Toll Free:	1 800 954 501
Sydney Local Dial:	02 8072 4187
Melbourne Local Dial:	03 9999 2409
Brisbane Local Dial:	07 3107 0241
Japan:	005 3116 1306
New Zealand:	0800 480 392
Singapore:	800 852 3140
United Kingdom:	0808 168 3761
United States/Canada:	1 855 336 4664

---ends---

This release has been approved by the Board of SomnoMed Limited

For further information please contact

Corporate

Mr. Neil Verdal-Austin

CEO SomnoMed

+61 406 931 477

Nverdalaustin@somnomed.com

Investors

Mr. Craig Sainsbury

Market Eye

+61 428 550 499

Craig.sainsbury@marketeye.com.au

Ms. Stephanie Ottens

Market Eye

+61 434 405 400

Stephanie.ottens@marketeye.com.au

About SomnoMed

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 630,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>